Ampersand Biosciences

Executive Summary

Ampersand Biosciences is a privately held biotechnology company that specializes in the development, manufacturing, and validation of custom multiplex immunoassay kits and testing services. Founded in 2019 and headquartered in San Francisco, the company focuses on providing critical tools for drug discovery, particularly through its unique Luminex-based cytokine panels designed for underrepresented animal models such as ferrets and hamsters. By addressing a gap in available reagents for these models, Ampersand enables researchers to conduct more relevant translational studies, potentially accelerating the development of vaccines and therapeutics for infectious diseases and other conditions. The company's offerings include custom assay development, sample testing services, and the sale of validated antibodies and proteins, positioning it as a niche supplier in the immunology and drug discovery ecosystem. With a lean operational model and a clear focus on an underserved market segment, Ampersand Biosciences has the potential to capture significant share within the preclinical research tools space. The increasing emphasis on reducing animal model reliance and improving translational predictivity could drive demand for its specialized services. However, as a pre-clinical stage company with no disclosed funding or revenue, its near-term viability depends on securing partnerships or investment to scale production and expand its product portfolio. The company's ability to establish collaborations with pharmaceutical developers or contract research organizations will be critical to its growth and market penetration.

Upcoming Catalysts (preview)

• TBDLaunch of expanded cytokine panels for additional animal models50% success
• TBDStrategic partnership or collaboration with a major pharmaceutical company40% success
• TBDSeries A funding round to scale manufacturing and sales60% success